2019
Author response: Non‐alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle‐aged adults: The Framingham study
Weinstein G, Davis‐Plourde K, Beiser AS, Seshadri S. Author response: Non‐alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle‐aged adults: The Framingham study. Liver International 2019, 40: 1240-1240. PMID: 31850659, DOI: 10.1111/liv.14318.Peer-Reviewed Original ResearchNon‐alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle‐aged adults: The Framingham Study
Weinstein G, Davis‐Plourde K, Himali JJ, Zelber‐Sagi S, Beiser AS, Seshadri S. Non‐alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle‐aged adults: The Framingham Study. Liver International 2019, 39: 1713-1721. PMID: 31155826, PMCID: PMC6736704, DOI: 10.1111/liv.14161.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseNAFLD fibrosis scoreFatty liver diseaseCognitive functionAdvanced fibrosisFibrosis scoreLiver diseaseBrain healthLower riskPresence of NAFLDRelationship of NAFLDLiver fibrosis scoresExcessive alcohol intakeVisceral adipose tissueSeverity of fibrosisPoor cognitive functionMiddle-aged adultsExecutive functionCross-sectional relationshipNAFLD diagnosisCardiometabolic variablesAlcohol intakeFramingham StudyInsulin resistancePotential confoundersAssociation of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: Pooled analysis from 5 cohorts
Weinstein G, Davis-Plourde KL, Conner S, Himali JJ, Beiser AS, Lee A, Rawlings AM, Sedaghat S, Ding J, Moshier E, van Duijn CM, Beeri MS, Selvin E, Ikram MA, Launer LJ, Haan MN, Seshadri S. Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: Pooled analysis from 5 cohorts. PLOS ONE 2019, 14: e0212293. PMID: 30768625, PMCID: PMC6377188, DOI: 10.1371/journal.pone.0212293.Peer-Reviewed Original ResearchConceptsInsulin useMRI measuresDementia/AD riskCognitive functionAssociation of metforminGlycemic control propertiesNew-onset dementiaSacramento Area Latino StudyCox regression analysisBrain MRI measuresPopulation-based cohortRisk of dementiaAdverse cognitive outcomesLife style changesGlobal cognitive functionFramingham Heart StudySulfonylurea useDiabetes medicationsReykjavik StudyGlycemic dysregulationRenal functionGlycemic controlRotterdam StudyDementia riskIncident dementia
2017
Atrial fibrillation and cognitive decline in the Framingham Heart Study
Nishtala A, Piers RJ, Himali JJ, Beiser AS, Davis-Plourde KL, Saczynski JS, McManus DD, Benjamin EJ, Au R. Atrial fibrillation and cognitive decline in the Framingham Heart Study. Heart Rhythm 2017, 15: 166-172. PMID: 28943482, PMCID: PMC5881912, DOI: 10.1016/j.hrthm.2017.09.036.Peer-Reviewed Original ResearchConceptsPrevalent atrial fibrillationVascular risk factorsAtrial fibrillationFramingham Heart StudyAF statusRisk factorsAPOE4 statusHeart StudyOffspring CohortVascular risk factor burdenCognitive performanceNP assessmentExecutive functionLongitudinal declineRisk factor burdenDomain-specific cognitive performanceApolipoprotein ε4 statusBaseline neuropsychological assessmentCross-sectional analysisInter-test intervalEligible participantsOriginal cohortVascular profilesΕ4 statusCognitive decline